CEO: Jon P. Stonehouse

Sector: Health Technology
Industry:Biotechnology

Exchange: NASDAQ

Country: US

Description: BioCryst Pharmaceuticals, Inc. designs and develops novel, oral and small-molecule medicines. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.


Key numbers

Market Capitalization:744412220
Shares Outstanding: 176401000
Float: 174003005
Next Earning Date:2020-08-06
TTm EPS: -0.9454
TTm Dividend Rate:
200 days moving average:3.3
50 days moving average: 4.73
One day percent Change: -3.55



2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,